Showing recent highlights
What's New
PubMed · August 25, 2026
Researchers found that in studies testing new Alzheimer's treatments, most trials measured things like memory and thinking skills, overall health status, and ability to handle daily tasks — but very few paid attention to the quality of life of patients or their caregivers. This matters because for someone living with Alzheimer's disease, how well they can enjoy daily life and how much strain falls on the people caring for them are hugely important, yet these pieces are often left out of the research picture. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a treatment called rTMS — which uses magnetic pulses directed at the brain to stimulate nerve activity — was being studied as a possible option for people with Alzheimer's disease, and this study looked closely at the side effects that occurred during that trial. They found that the most common side effects were general pain or discomfort and muscle twitching, and that higher levels of stimulation tended to be linked to more of these physical side effects. This matters because understanding who is more likely to experience side effects, and why, could help make the treatment safer and more comfortable for people with Alzheimer's if it moves forward. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with early Alzheimer's disease or mild memory problems who did six months of structured brain-training exercises on a computer showed meaningful improvements in memory, daily functioning, and anxiety — and also had lower levels of inflammation in their blood (inflammation is the body's overactive response that can contribute to brain damage over time). What made this especially interesting is that brain scans still showed the disease progressing, yet people's thinking and daily skills improved anyway, suggesting the brain may find new ways to cope even as it changes. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 23, 2026
Researchers found that three non-drug brain stimulation approaches — using light, mild electrical currents, or magnetic pulses applied to the head — all helped improve thinking and memory in people with Alzheimer's disease, compared to no treatment. Of the three, light-based therapy (called photobiomodulation) showed the strongest improvements in cognitive tests, which measure things like memory, attention, and reasoning. This is early research and hasn't yet changed treatment guidelines.
What's New
JAMA · July 21, 2026
Researchers found that measuring the exact amount of a brain protein called amyloid — which builds up in people with Alzheimer's disease — may give doctors more useful information than simply saying it's either 'present' or 'absent.' This more detailed measurement, called a Centiloid value, could help doctors make better decisions about diagnosis and treatment for people experiencing early memory and thinking problems. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · July 20, 2026
Researchers found that the brain's own immune cells — called microglia — may be a key reason why people with Alzheimer's disease often struggle to get deep, restful sleep. In mice, these immune cells were overactive and caused inflammation that disrupted sleep, and reducing them restored over two hours of sleep per day — even without removing the protein build-up (called plaques) that Alzheimer's is known for. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · July 17, 2026
A press release describes early findings around a drug called KCL-286, which was first created to treat spinal cord injuries but is now being looked at for Alzheimer's disease. In animal studies, it helped repair damage to cells' DNA (the genetic instructions inside cells), reduced swelling and irritation in the brain, and seemed to target several disease processes at once rather than just one. Because the drug has already passed an early human safety test, scientists are hopeful it could be tested in people with Alzheimer's sooner than a brand-new drug would be.
What's New
PubMed · July 15, 2026
Researchers found that a traditional Japanese herbal formula called Yokukansan helped reduce behavioral and psychological symptoms — things like agitation, anxiety, and sleep problems — in people with Alzheimer's disease more effectively than a placebo (a dummy treatment with no active ingredients) over four weeks. However, the formula did not show a clear improvement in memory or thinking ability during that same period. This is early research and hasn't yet changed treatment guidelines.
What's New
JAMA · July 14, 2026
Researchers have been studying ways to prevent Alzheimer's disease, and this article looks back at 50 years of progress in that effort — which is encouraging news for the millions of people and families affected by this condition. Understanding what helps prevent Alzheimer's could eventually help doctors catch the disease earlier or reduce the chances of it developing in the first place. This is early research and hasn't yet changed treatment guidelines.
What's New
The Lancet · July 13, 2026
Researchers found that older adults in Latin America who were at risk of memory and thinking problems showed greater improvements in brain function when they followed a structured program focused on multiple healthy lifestyle changes — things like diet, exercise, and social activity — compared to those who just received general health advice. This is exciting because it suggests that lifestyle changes may help protect the brain, and the findings included people from communities that are often left out of this kind of research. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 13, 2026
Researchers found that AI tools called large language models — the same technology behind chatbots like ChatGPT — show some promise for helping with Alzheimer's disease tasks like answering patient questions and supporting diagnosis, but they come with real limitations. These AI systems sometimes generated inaccurate information, were often written at a reading level too difficult for most patients, and didn't consistently match established medical guidance when it came to treatment decisions. For people affected by Alzheimer's disease or early memory problems, this matters because it suggests AI tools aren't yet reliable enough to replace a doctor's judgment or serve as a trusted source of medical information on their own. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 8, 2026
Researchers found that reality orientation therapy — a non-drug approach where caregivers and staff regularly remind people with dementia of things like the date, their surroundings, and familiar people — may help improve thinking and memory skills and reduce feelings of depression in people with dementia. However, it didn't show a clear benefit for everyday tasks like dressing or bathing, or for other emotional and behavioral symptoms that can come with dementia. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that AI systems trained to look at multiple types of information at once — such as brain scans, blood tests, genetic data, and memory assessments — were better at spotting early signs of Alzheimer's disease than systems relying on just one type of information alone. This matters because catching Alzheimer's earlier could give people and their doctors more time to plan and potentially slow the disease's progression. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · July 1, 2026
A study found that people with Alzheimer's disease who joined live, online group exercise sessions three times a week for six months — done from home via video call — got stronger arms and had better stamina compared to those who didn't join the sessions. Researchers measured this using arm curl repetitions and a two-minute stepping test, and both improved meaningfully for the exercise group. The study also found that the caregivers who exercised alongside their loved ones saw similar physical improvements, suggesting the program may have benefited both people at once.
What's New
PubMed · June 29, 2026
Researchers found that a human-shaped social robot — designed to interact with and engage people — helped improve the mood and reduce feelings of depression in people with Alzheimer's disease and related conditions over an 8-week period. Participants also found the robot easy and enjoyable to use, which matters because depression is a very common and distressing part of living with Alzheimer's, and finding non-medication ways to help can be meaningful. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · June 19, 2026
Scientists discovered a molecule called OLE that may help the brain's own immune cells — the cells that normally protect the brain from damage — work better in people with Alzheimer's disease. In lab models, this molecule reduced the buildup of harmful clumps in the brain (called plaques) that are linked to Alzheimer's, and it also improved memory. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · June 16, 2026
A copper-based drug — meaning a medicine that contains the metal copper as part of its active ingredient — was found to help the brain clean out harmful proteins that build up in Alzheimer's disease, and it improved memory in lab experiments. This is exciting partly because the drug has already been tested in people for other brain conditions, which could potentially speed up the path to making it available for Alzheimer's patients. This is early research and hasn't yet changed treatment guidelines.
Medications
JAMA · June 16, 2026
Researchers found that the FDA approved a new medication specifically designed to help treat agitation — meaning episodes of restlessness, aggression, or emotional distress — in people living with Alzheimer's disease dementia. This is a new option, as it marks an official approval for this particular use rather than a safety update or guideline change. The name of the specific medication wasn't included in the provided text, but the approval signals that a treatment has met the FDA's standards for both safety and effectiveness for this purpose.
Ask your doctor: Ask the doctor whether this new FDA-approved medication for agitation might be something the patient should know about or consider if the patient or a family member is dealing with agitation from Alzheimer disease.
What's New
ScienceDaily · June 10, 2026
A study found that people who take glucosamine — a popular supplement often used for joint pain — may be more likely to see their memory and thinking problems get worse over time. Researchers found a 25% higher chance of progressing to Alzheimer's disease among glucosamine users, and they also identified some biological clues that might help explain the connection. This could matter for people living with early memory concerns, since many people take glucosamine regularly without realizing it might affect brain health.
Ask your doctor: Ask the doctor whether the patient should stop taking glucosamine since a recent study found it might be linked to faster progression of Alzheimer's disease.
Medications
PubMed · June 1, 2026
A study found that a drug called donanemab (brand name Kisunla) may help slow the progression of early Alzheimer's disease. Researchers found that it reduced the chance of people moving from mild memory problems to more serious stages of the disease — for example, cutting the risk of progressing from mild to moderate Alzheimer's by about half. This appears to be a new treatment option, not a safety update or guideline recommendation, and it works by targeting a sticky protein buildup in the brain linked to Alzheimer's.
Ask your doctor: Ask the doctor whether donanemab might help slow down the patient's memory and thinking problems if the patient has early Alzheimer disease or mild cognitive impairment.
Lifestyle
PubMed · June 1, 2026
Researchers found that spending structured time with a therapy dog — sessions repeated regularly as part of a formal program — significantly reduced troubling behaviors in people with dementia, such as depression, withdrawal, and agitation (which doctors call behavioral and psychological symptoms of dementia, or BPSD). Compared to people who received only routine care, those who had dog-assisted therapy sessions also showed improvement in their ability to carry out everyday activities. The researchers pooled results from 10 separate studies to reach these findings.
What's New
PubMed · June 1, 2026
Researchers found that a personalized mental exercise program — where patients work one-on-one on memory and thinking activities — helped improve memory in people with moderate Alzheimer's disease, but did not show the same benefit for those whose Alzheimer's had progressed further. This suggests that the timing of when someone starts this kind of brain-stimulating activity may matter, with earlier intervention potentially being more helpful. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a diabetes medication like Ozempic or Victoza may help slow memory and thinking decline in people with type 2 diabetes who also have dementia or Alzheimer's disease — a condition that causes progressive memory loss. Several large research reviews pointed to real improvements in learning and thinking skills among people taking these medications. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that several treatments — both medical and non-medical — may help improve thinking and memory in people with Alzheimer's disease. Two approaches stood out as especially promising: 'photobiomodulation' (using specific light therapy directed at the brain) and 'enriching environment' (filling daily life with mentally stimulating activities, social interaction, and sensory experiences), both of which appeared to work better than standard medications or exercise alone. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that acupuncture may help improve thinking and memory skills in people with Alzheimer's disease or mild cognitive impairment — a condition where memory problems are noticeable but not yet severe enough to be called dementia. Looking at 52 studies involving more than 3,300 patients, they found that acupuncture on its own performed better than no treatment or a placebo, and that combining acupuncture with standard medications worked better than medications alone. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether acupuncture might help improve the patient's memory and thinking abilities, based on recent research showing it may work better than placebo treatments.
Lifestyle
PubMed · June 1, 2026
A study found that following the MIND diet — an eating plan that emphasizes vegetables, berries, nuts, whole grains, fish, and olive oil while limiting red meat, butter, and sweets — was linked to slower cognitive decline over three years in older adults who had certain biological markers in their blood associated with Alzheimer's disease risk. Researchers tracked over 600 adults between the ages of 65 and 84, and those with higher levels of these Alzheimer's-related markers in their blood appeared to benefit most from sticking closely to the MIND diet. The findings suggest that what a person eats regularly may play a role in how quickly thinking and memory change over time, particularly for those whose bodies already show early signs associated with Alzheimer's disease.
What's New
PubMed · May 30, 2026
Researchers found that a diabetes medication like Ozempic or Victoza (taken as a daily pill) did not slow the worsening of memory and thinking problems in people with early-stage Alzheimer's disease, even though earlier hints from animal and real-world studies had suggested it might help protect the brain. The large study followed nearly 3,800 people across 40 countries for about two years, but ultimately the trials were stopped early because the treatment did not show the hoped-for benefit. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 12, 2026
Researchers found that people with early signs of Alzheimer's disease in their brain — like buildup of harmful proteins — didn't all experience the same level of memory and thinking problems. Those with more years of education, higher socioeconomic status (meaning greater financial and social resources), and healthier brain structure tended to hold onto their thinking skills better, even when those harmful protein levels were high. This matters because it suggests that factors like education and overall brain health may act as a kind of cushion, helping the brain cope longer before symptoms become noticeable. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 4, 2026
Researchers found that a simple blood test measuring a protein called p-tau217 — a marker of the brain changes seen in Alzheimer's disease — was highly accurate at detecting the condition, correctly identifying it about 85–88% of the time. This matters because current methods to diagnose Alzheimer's often require expensive brain scans or a spinal tap, which involves inserting a needle into the lower back to collect fluid — both of which can be hard to access or uncomfortable for patients. A routine blood draw could one day make earlier, easier diagnosis possible for more people. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 1, 2026
Researchers found that loneliness may play a significant role connecting Alzheimer's disease and suicidal thoughts or behaviors — people who felt lonely were nearly twice as likely to develop Alzheimer's disease, and those feelings were also strongly linked to a higher chance of thinking about, planning, or attempting suicide. The researchers also found that feelings of being trapped, hopelessness, poor sleep, and stress were closely tied to loneliness in people with Alzheimer's disease, with depression being the most common thread running through all of these connections. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.